Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22463649 | 1.00 | OPRL1 (0.40) | OPRL1CYP11B1CYP11B2IDO1TRPA1 | |
| SCHEMBL28680489 | 0.85 | OPRL1 (0.44) | OPRL1CYP11B1CYP11B2IDO1TRPA1 | |
| SCHEMBL29368373 | 0.85 | OPRL1 (0.44) | OPRL1CYP11B1CYP11B2IDO1TRPA1 | |
| SCHEMBL28680491 | 0.85 | OPRL1 (0.44) | OPRL1CYP11B1CYP11B2IDO1TRPA1 | |
| SCHEMBL14615235 | 0.84 | CYP11B1 (0.46) | OPRL1CYP11B1CYP11B2CYP2A6SIRT3 | |
| SCHEMBL14614990 | 0.84 | CYP11B1 (0.46) | OPRL1CYP11B1CYP11B2CYP2A6SIRT3 | |
| SCHEMBL12480153 | 0.76 | GAA (0.42) | P2RX7CYP17A1TSHRCHRNB2CHRNA4 | |
| SCHEMBL15571238 | 0.76 | LOXL2 (0.38) | TSHRCHRNB2CHRNA4 | |
| SCHEMBL745178 | 0.76 | AXL (0.32) | TSHR | |
| SCHEMBL16132536 | 0.75 | OPRL1 (0.57) | OPRL1IDO1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109671-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12448352-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3946329-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | Curasen Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020198466-A9 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| WO-2020198466-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2675459-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | Medivation Technologies, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2675458-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | Medivation Technologies, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| CN-103476417-A | Compounds and methods of treating diabetes | MEDIVATION TECHNOLOGIES INC | 2013-12-25 | — | — | CN | disclosed |
| CN-103476416-A | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES INC | 2013-12-25 | — | — | CN | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012112966-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | OPRL1 33/4885CYP11B1 84/4885CYP11B2 49/4885 |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | OPRL1 33/4885CYP11B1 84/4885CYP11B2 49/4885 |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | OPRL1 366/4885CYP11B1 67/4885CYP11B2 53/4885 |
| US-12448352-B2 | Beta adrenergic agonist and methods of using the same | ADRA2B, ADRB2, ADRB1 | OPRL1 42/4885CYP11B1 272/4885CYP11B2 207/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | OPRL1 438/4885CYP11B1 177/4885CYP11B2 67/4885 |
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | OPRL1 33/4885CYP11B1 84/4885CYP11B2 49/4885 |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | OPRL1 366/4885CYP11B1 67/4885CYP11B2 53/4885 |
| US-11040944-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | OPRL1 33/4885CYP11B1 84/4885CYP11B2 49/4885 |
| US-20260109671-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | OPRL1 23/4885CYP11B1 508/4885CYP11B2 293/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | OPRL1 424/4885CYP11B1 176/4885CYP11B2 69/4885 |
| US-20220169612-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRA2B, ADRB2, ADRB1 | OPRL1 42/4885CYP11B1 272/4885CYP11B2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.